

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

**CLARIFICATION ANNOUNCEMENT
GRANT OF SHARE OPTIONS AND
GRANT OF RESTRICTED SHARE UNITS**

Reference is made to the announcement of the Company dated June 5, 2023 (the “**Announcement**”) relating to, among others, the grant of share options under the share option scheme of the Company. Unless otherwise stated, defined term used in this announcement shall have the same meaning used in the Announcement.

The Company wishes to clarify that the correct exercise price of each Share Option and the average closing price of the Shares as stated in the daily quotation sheet of the Stock Exchange for the five business days immediately preceding the Date of Grant as stated in the Announcement should be “HK\$10.434” instead of “HK\$10.43”.

Save as disclosed above, the rest of the Announcement remains unchanged.

By order of the Board
SciClone Pharmaceuticals (Holdings) Limited
PAN Rongrong
*Executive Director, Chief Financial Officer and
Joint Company Secretary*

Hong Kong, June 7, 2023

As at the date of this announcement, the Board comprises Mr. Zhao Hong and Ms. Pan Rongrong as executive directors, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* *for identification purpose only*